Wenbin Jiang, Ph.D. has served as Cytek’s Chief Executive Officer and a member of our board of directors since December 2014 and serves as chair of our board. Dr. Jiang is also a co-founder of the company. In 1998, Dr. Jiang co-founded E2O Communications, Inc., a fiber optic subsystems manufacturing company, which was acquired by JDS Uniphase Corporation in 2004.

Dr. Jiang is an inventor of more than 100 U.S. patents and an author of five book chapters and over 50 peer-reviewed technical papers.

Dr. Jiang holds a B.S. in Physics and a M.S. in Optics & Laser Physics from Fudan University and a Ph.D. in Electrical Engineering from University of California, Santa Barbara.

Dr. Jiang is currently serving on the Board of Trustees of the UC Santa Barbara Foundation and the Director’s Council in the Institute for Energy Efficiency at UC Santa Barbara.

Richard Chin, M.D., has served on our board of directors since June 2025. Since January 2026, he has served as the Chief Executive Officer of EmberWorks, LLC, an off-grid telecommunications company, and has also served as the Chief Executive Officer and a board member of AdoraPet Biosciences, Inc., a biotechnology startup focused on pets, since August 2022. Since September 2021, Dr. Chin has served as the managing director of Ascendant Venture LLC, a family office and venture studio that has incubated several life sciences companies. From 2012 to 2021, he served as Chief Executive Officer and a board member of Kindred Biosciences, Inc., a public biotechnology company focused on companion animals that was acquired by Elanco in 2021. From 2008 to 2011, Dr. Chin served as Chief Executive Officer of Institute for OneWorld Health, a non-profit biotechnology company developing drugs for neglected diseases. In addition, from 2006 to 2008, he served as Chief Executive Officer of OXiGENE, Inc., a public biotechnology company developing vascular targeting drugs for oncology and ophthalmology. Prior to that, Dr. Chin served in various leadership roles in clinical development and medical affairs. He currently serves on the board of directors of several private bioscience companies, including Bio Usawa Inc., VETmAb Biosciences, Inc. and Lifeguard Biosciences, Inc., as well as two non-profit organizations, the Center for Asian American Media and the Sand Mandala Foundation. Dr. Chin holds a B.A. in biology from Harvard College, an M.A. and B.A. in law from Oxford University, and a medical degree from Harvard Medical School.

Michael Holder has served on our board of directors since June 2024. Since December 2023, Mr. Holder has served as the Principal of Gloria Consulting Partners LLC, an executive management, business strategy, and financial consulting company. He also served as Chief Executive Officer of Sensable Health Inc., a privately held wellness company, from July 2024 to June 2025. Prior to that, Mr. Holder served as Chief Financial Officer of AVITA Medical Inc., a publicly traded regenerative medicine company, from March 2021 to January 2023; as Chief Financial Officer of ImmuneCyte Inc., a privately held biopharmaceutical company, from July 2020 to January 2021; as Chief Executive Officer and Portfolio Manager of Carolina Longevity Institute, LLC, a biotech and medtech private investment company, from 2017 to 2019; as Chief Executive Officer and Chief Financial Officer of Organ Transport Systems Inc, a privately held medical device company, from 2010 to 2017 and 2005 to 2010, respectively; as Vice President of Sales, Operations and Finance, and Chief Financial Officer for Premier Sourcing Partners Inc., a wholly owned subsidiary of Premier Inc., a privately held medical and information technology product and services company, from 2002 to 2004 and 2000 to 2002, respectively; as Chief Financial Officer of Clarkston-Potomac Group, a privately held ERP implementation and integration services company, from 1998 to 2000; and as Chief Financial Officer of Beacon Eye Institute, a publicly traded provider of Laser Vision Correction equipment and services from 1996 to 1998. Since May 2025, Mr. Holder has served as a member of the board of directors and audit committee chair of MDxHealth SA, a publicly traded molecular oncology company, and, from July 2025 to March 2026, served as non-executive chair and member of the board of directors of Hollywood Expansion Corporation, a privately held film and entertainment company. Mr. Holder also served as a member of the board of directors of Keyron Ltd, a privately held medical device company based in the U.K. from December 2022 to July 2025; as a member of the board of directors of Carolina Longevity Institute, LLC from 2017 to 2019, and as a member of the board of directors of Limitless LLC, a privately held nutraceutical research and development company, from 2018 to 2019. Mr. Holder also served on the board of directors of Organ Transport Systems, Inc. from 2005 to 2017, and Cyphre Inc., a privately held cybersecurity company, from 2016 to 2017. Mr. Holder holds a B.S. in Business Administration from The Kenan-Flagler Business School at the University of North Carolina at Chapel Hill, and an M.B.A. with a major in Corporate Strategy and Finance from The Wharton School at the University of Pennsylvania. Mr. Holder previously obtained his certified public accountant license (currently inactive). He has attended board education programs at Harvard Business School.

Vera Imper, Ph.D. has served on our board of directors since December 2021. Dr. Imper served as Vice President and Head, Business Development of Roche Molecular Solutions from January 2018 to November 2021. Dr. Imper previously served as Vice President, Worldwide Business Development of Becton Dickinson Biosciences from May 2009 to October 2017. Dr. Imper currently serves on the advisory board of Barcode Nanotech, a privately funded start-up company. Dr. Imper holds a B.S. in Pharmacy and Biochemistry, an M.S. in Physical and Organic Chemistry, and a Ph.D. in Bioinorganic Chemistry from the University of Zagreb.

Glenn P. Muir has served on our board of directors since June 2026. Mr. Muir served as Chief Financial Officer and Executive Vice President of Finance and Administration of Hologic, Inc., a publicly traded manufacturer and supplier of medical products, from 2000 until he retired in 2014. He also served as Hologic’s Chief Financial Officer and Vice President of Finance and Administration from 1992 to 2000 and as Controller from 1988 to 1992. Prior to then, Mr. Muir served as Chief Financial Officer and Vice President of Finance and Administration at Metallon Engineered Materials Corp. from 1986 to 1988. He served as a Senior Auditor with Arthur Andersen & Co. from 1981 to 1984. Mr. Muir has served as a member of the board of directors of Repligen Corporation, a publicly traded life science company, since 2015 and as chair of its audit committee since 2016, and as a member of the board of directors of Neuronetics, Inc., a publicly traded medical technology company, since 2017 and as the current chair of its audit committee. Mr. Muir also served as a member of the board of directors of G1 Therapeutics, Inc., a publicly traded biotechnology company, from 2015 until September 2024, when it was acquired. He served as an independent director of ReWalk Robotics Ltd. and RainDance Technologies, Inc., both from 2014 to 2017. Mr. Muir holds a B.S. in Accounting from the University of Massachusetts in Amherst, an M.B.A. from the Harvard Business School, and an M. Sc. in Taxation from Bentley College Graduate School of Business. Mr. Muir previously obtained his certified public accountant license (inactive since 2022).

Deborah Neff has served on our board of directors since June 2022 and has served as our lead independent director since February 2025. Since 2020, she has served as the Principal of DJN Consulting, LLC, an executive management, business strategy and operations consulting company. Prior to that, from 2017 to 2020, she served as Chief Executive Officer of Evanostics LLC, an early-stage, private biotechnology company. From 2014 to 2016, she served as the Chief Operating Officer of Complete Genomics Inc., a business unit of BGI-Shenzhen, a publicly traded genomic sequencing and proteomic services company. From 2006 to 2013, she served as the Chief Executive Officer at Pathwork Diagnostics Inc., a privately held molecular diagnostics company, and from 2003 to 2006, she served as the Chief Executive Officer at Predicant Biosciences, formerly a private biotechnology company. Ms. Neff also served as President of BD Biosciences, Inc., a global business segment of Becton Dickinson, from 1995 to 2003. Ms. Neff served as a director on the board of Atomo Diagnostics Limited, an Australian publicly listed rapid diagnostics company, from October 2021 to May 2025, on the advisory board of privately funded start-up company Wainamics, Inc. from March 2021 to February 2025, on the board of directors of Bio-Rad Laboratories, Inc. from 2011 to 2017, and on the board of directors of Advanced Medical Optics, Inc. from 2003 to 2009. Ms. Neff has served as the Executive Trustee and Chair of the University of California, Davis Foundation since 2021, as chair of the board of directors of Guide Dogs for the Blind since July 2024 and as a member of the board since February 2022, and on the advisory board of privately funded start-up company Partillion Bioscience Corporation since August 2020. Ms. Neff holds a B.S. degree in Physiology from the University of California, Davis and completed graduate training and licensure in clinical laboratory science. She has attended executive business programs in finance, marketing, and general management at Wharton, Stanford, and Harvard Business Schools.

Ming Yan, Ph.D. has served as the Chief Technology Officer and a member of our board of directors since 2015. Dr. Yan is also a co-founder of the company. Dr. Yan has over 20 years of experience in research and development. Prior to joining our company, Dr. Yan held research and development positions at AT&T Bell Laboratories, a research and development division of AT&T Communications, a telecommunications company, Lawrence Livermore National Labs, a federal research facility, and BD Biosciences, a biotechnology company. Dr. Yan has published several research papers relating to laser spectroscopy and cell analysis in top peer-reviewed journals. He has over a dozen patents and pending patent applications for his innovations. Dr. Yan holds a B.S. in Physics from Fudan University and a Ph.D. in Electrical Engineering from the City University of New York.